Has Neda Kalhor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $29,500 in general payments to Neda Kalhor, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neda Kalhor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neda Kalhor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neda Kalhor, MD

Cytopathology · Houston, TXNPI 1881869485

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,474 of the $29,500 with a category attached, or 89.7%. Merck accounts for 73.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $7,883 and has fallen 71.4% since, to $2,258 in 2025. Among cytopathology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,500in general payments, 2019–2025

Across 27 payments — averaging $1092.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$22K
E.r. Squibb & Sons, L.L.C.$7K
Astrazeneca UK Limited$1K
Stemline Therapeutics Inc.$65

What the payments were for

Consulting fees$26,47490%
Travel & lodging$2,6219%
Food & beverage$4061%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	21	$21,558
E.r. Squibb & Sons, L.L.C.	3	$6,514
Astrazeneca UK Limited	2	$1,364
Stemline Therapeutics Inc.	1	$65

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KEYTRUDA$12,495

How this compares

$29,500 in reported general payments places this provider in the 95th percentile of 24 cytopathology providers in Texas.

See all cytopathology providers in Texas →

Medicare billing

Part B allowed, 2024

$77,145

Medicare patients

710

Services billed

1,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cytopathology in Houston

William SymmansHouston$9K
Kidada Gilbert-LewisHouston$828
Linda GreenHouston$223
Ming GuoHouston$176
Yun GongHouston$86
Xiao HuangHouston$86
Christina FanningHouston$72
John StewartHouston$39
Gordana VerstovsekHouston$14
Luis de Las CasasDallas$10K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →